These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19719912)

  • 1. [Pharmacoeconomic evaluation of telbivudine vs. lamivudine in treating the patients with HBeAg-positive and negative chronic hepatitis B].
    Chen W; Hou JL
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):569-73. PubMed ID: 19719912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis.
    Wu B; Li T; Chen H; Shen J
    Value Health; 2010 Aug; 13(5):592-600. PubMed ID: 20561341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telbivudine for the treatment of chronic hepatitis B infection.
    Hartwell D; Jones J; Harris P; Cooper K
    Health Technol Assess; 2009 Oct; 13 Suppl 3():23-30. PubMed ID: 19846025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of telbivudine versus lamivudine for chronic hepatitis B.
    Wiens A; Venson R; Correr CJ; Pontarolo R
    Braz J Infect Dis; 2011; 15(3):225-30. PubMed ID: 21670922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan.
    Veenstra DL; Sullivan SD; Lai MY; Lee CM; Tsai CM; Patel KK
    Value Health; 2008; 11(2):131-8. PubMed ID: 18380625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine.
    Almeida AM; da Silva AL; Cherchiglia ML; Andrade EI; de Oliveira GL; Acurcio Fde A
    Value Health; 2011; 14(5 Suppl 1):S24-8. PubMed ID: 21839893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy.
    Lui YY; Tsoi KK; Wong VW; Kao JH; Hou JL; Teo EK; Mohamed R; Piratvisuth T; Han KH; Mihm U; Wong GL; Chan HL
    Antivir Ther; 2010; 15(2):145-55. PubMed ID: 20386069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan.
    Sullivan SD; Veenstra DL; Chen PJ; Chang TT; Chuang WL; Tsai C; Patel K
    J Gastroenterol Hepatol; 2007 Sep; 22(9):1494-9. PubMed ID: 17716353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.
    Lee KK; Wu DB; Chow PY; Lee VW; Li H
    J Gastroenterol Hepatol; 2012 Jul; 27(7):1167-74. PubMed ID: 22141402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B.
    Arnold E; Yuan Y; Iloeje U; Cook G
    Appl Health Econ Health Policy; 2008; 6(4):231-46. PubMed ID: 19382822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.
    Buti M; Brosa M; Casado MA; Rueda M; Esteban R
    J Hepatol; 2009 Oct; 51(4):640-6. PubMed ID: 19576651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.
    Liaw YF; Gane E; Leung N; Zeuzem S; Wang Y; Lai CL; Heathcote EJ; Manns M; Bzowej N; Niu J; Han SH; Hwang SG; Cakaloglu Y; Tong MJ; Papatheodoridis G; Chen Y; Brown NA; Albanis E; Galil K; Naoumov NV;
    Gastroenterology; 2009 Feb; 136(2):486-95. PubMed ID: 19027013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand.
    Tantai N; Chaikledkaew U; Tanwandee T; Werayingyong P; Teerawattananon Y
    BMC Health Serv Res; 2014 Apr; 14():170. PubMed ID: 24731689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telbivudine versus lamivudine in patients with chronic hepatitis B.
    Lai CL; Gane E; Liaw YF; Hsu CW; Thongsawat S; Wang Y; Chen Y; Heathcote EJ; Rasenack J; Bzowej N; Naoumov NV; Di Bisceglie AM; Zeuzem S; Moon YM; Goodman Z; Chao G; Constance BF; Brown NA;
    N Engl J Med; 2007 Dec; 357(25):2576-88. PubMed ID: 18094378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B.
    Spackman DE; Veenstra DL
    Pharmacoeconomics; 2008; 26(11):937-49. PubMed ID: 18850763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness and cost-utility of the treatment of chronic hepatitis B with peginterferon alfa-2a, interferon alfa, and lamivudine in Lithuania.
    Vanagas G; Padaiga Z; Mickevičienė A
    Medicina (Kaunas); 2010; 46(12):835-42. PubMed ID: 21532288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.
    Hou J; Yin YK; Xu D; Tan D; Niu J; Zhou X; Wang Y; Zhu L; He Y; Ren H; Wan M; Chen C; Wu S; Chen Y; Xu J; Wang Q; Wei L; Chao G; Constance BF; Harb G; Brown NA; Jia J
    Hepatology; 2008 Feb; 47(2):447-54. PubMed ID: 18080339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program.
    Yuan Y; Iloeje U; Li H; Hay J; Yao GB
    Value Health; 2008 Mar; 11 Suppl 1():S11-22. PubMed ID: 18387054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom.
    Veenstra DL; Sullivan SD; Dusheiko GM; Jacobs M; Aledort JE; Lewis G; Patel KK
    Eur J Gastroenterol Hepatol; 2007 Aug; 19(8):631-8. PubMed ID: 17625431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore.
    Lacey LF; Gane E
    J Viral Hepat; 2007 Nov; 14(11):751-66. PubMed ID: 17927611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.